Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.

GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in ≥ 2-step improvement in DRSS (treatment) and 89% decreased risk of developing sight-threatening complications (prevention).